CAR-NK cell therapy: promise and challenges in solid tumors

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor T-cell (CAR-T) therapies are established treatments for hematologic cancers.
• Challenges with CAR-T therapy include autologous product manufacturing and toxicity management.
• Natural killer (NK) cells offer potential for universal, off-the-shelf cell therapies.

Purpose of the Study:

• To review current trends and emerging concepts in engineering next-generation CAR-NK therapies.
• To discuss the application of CAR-NK cells in solid tumors.
• To examine the advantages, limitations, and future challenges of CAR-NK therapies.

Main Methods:

• Review of current literature on CAR-NK cell therapy.
• Discussion of CAR-NK cell construction and target identification.
• Analysis of CAR-NK mechanisms of action and research status in solid tumors.

Main Results:

• First-in-human trials of CD19-CAR-NK cells show safety and clinical activity in lymphoid malignancies.
• Research is ongoing to enhance CAR-NK cell persistence and combat functional exhaustion.
• Growing interest exists in applying CAR-NK therapies to solid tumors.

Conclusions:

• CAR-NK cells present a promising avenue for next-generation cellular immunotherapy.
• Further research is needed to optimize CAR-NK therapy for broader applications, including solid tumors.
• Engineering CAR-NK cells holds potential for improved cancer treatment strategies.